Inhalers

Subsidiary of H&T Group. World's leading manufacturer of aluminum MDI canisters and plastic actuator components. Claims components used in 85% of global MDIs. Operates the Inhalation Product Technology Centre (IPTC) at Blackburn, UK for low-GWP propellant development.

Division of Orbia (formerly Mexichem). World leader in pharmaceutical-grade HFA propellants under the Zephex brand. Zephex 134a in ~75% of global pMDIs. Only FDA-registered active HFA-134a supplier in the US. Opened world's first commercial HFA-152a pharmaceutical manufacturing facility at Runcorn, UK in March 2022.

World's leading pMDI metering valve supplier. Its BK357 valve platform is used in more pMDI products globally than any other. Also provides CDMO fill-finish services for pMDIs and DPIs. Partnered with H&T Presspart on sustainable pMDI supply chain transition.

Specialty pharmaceutical-grade lactose company (HQ Goch, Germany; joint venture between Fonterra Co-operative Group and FrieslandCampina); the world's largest producer of pharmaceutical-grade lactose for use as a drug excipient in tablets, capsules, and dry powder inhalers. DFE Pharma's lactose (Pharmatose® brand) is used in the vast majority of pharmaceutical tablet and capsule formulations globally — most pills you take contain DFE Pharma lactose as a filler, flow agent, or binder. DFE Pharma's manufacturing combines Fonterra (NZ) lactose raw material expertise with FrieslandCampina (NL) processing capability. The same Fonterra-FrieslandCampina lactose joint venture that makes the excipient in most of the world's pharmaceutical tablets also produces food-grade lactose for infant formula.

German dairy and pharmaceutical excipient company. Through its InhaLac product line, one of two dominant global suppliers of inhalation-grade lactose monohydrate for DPI formulations. Inhalation lactose is a high-value niche — technically demanding particle size engineering from dairy lactose.

Japanese healthcare equipment company (OMRON Corporation subsidiary; HQ Muko, Kyoto Prefecture; OMRON Corporation TSE: 6645); makes mesh nebulizers (MicroAIR NE-U22 series) and manufactures vibrating mesh membranes in-house using precision photo-etching and electroforming processes at its Japanese manufacturing facilities. OMRON Healthcare is the world's leading mesh nebulizer manufacturer by volume, and its MicroAIR technology uses titanium or stainless steel mesh membranes with 2,700-6,000 holes of 2.1-5.7 μm diameter, produced using semiconductor-grade precision etching processes. OMRON is a Japanese industrial conglomerate whose products span: industrial automation robots (the largest revenue segment), healthcare monitors (blood pressure monitors, thermometers, glucose meters), and drug delivery devices (nebulizers). The same OMRON that makes blood pressure cuffs sold at CVS also makes the precision titanium mesh through which albuterol passes in a hospital ICU nebulizer therapy session.

American drug delivery and packaging company (NYSE: ATR, HQ Crystal Lake IL; ~$3.5B revenue); Aptar Pharma division produces drug delivery devices and components including injectable drug delivery systems, needle-free injection components, and parenteral packaging. For IV bag applications, Aptar supplies injection site components and additive port systems. Aptar also produces metered-dose inhaler (MDI) valves for asthma inhalers (a major product line), nasal spray pumps, and eye dropper closures. The same Aptar company that makes the pumping mechanism in your nasal allergy spray also supplies components for IV bag injection ports.

UK pharmaceutical company; sole manufacturer and formulator of AS01B adjuvant system (QS-21 + MPL in liposomes); used in Shingrix (herpes zoster vaccine, $4B+ annual revenue) and RTS,S/Mosquirix (malaria vaccine); retaining AS01E adjuvant supply even as malaria vaccine manufacturing transfers to Bharat Biotech

German respiratory medical device company (HQ Starnberg, Bavaria; private, founded 1906); a specialist inhaler and nebulizer manufacturer whose eFlow® technology (LC Sprint nebulizer, eFlow rapid) uses vibrating perforated membranes to generate pharmaceutical aerosols without heating the drug. PARI's eFlow mesh nebulizers are used for inhalation of antibiotics (tobramycin for cystic fibrosis — Cayston via Altera nebulizer), colistin, and experimental therapies where drug stability limits pMDI use. PARI manufactures its vibrating mesh membranes through European precision metalworking partnerships. PARI was founded in 1906 (pre-World War I) in Munich as an atomizer manufacturer — making it one of the oldest respiratory drug delivery device companies in the world. PARI's nebulizers are the device of choice for cystic fibrosis patients requiring daily antibiotic inhalation therapy — a demanding use case where mesh membrane longevity and aerosol consistency are life-critical.

Dutch healthcare technology company (Euronext: PHIA, HQ Amsterdam; ~$18B revenue); Respironics division (acquired from Respironics Inc. 2008) produces mesh nebulizers (InnoSpire Go, SideStream) as part of its respiratory care portfolio. Philips Respironics was severely damaged by the 2021 recall of ~4 million CPAP machines (Continuous Positive Airway Pressure for sleep apnea) due to sound abatement foam that was found to degrade into potentially carcinogenic particles — the largest medical device recall in US history by value (~$1.5B settlement, regulatory sanctions, CEO resignation). The Philips CPAP recall, while unrelated to its nebulizer products, significantly damaged the company's reputation, financial position, and regulatory standing — creating uncertainty about its nebulizer product line continuity. A CPAP foam degradation problem in sleep apnea devices created supply chain uncertainty for mesh nebulizers used by hospital COPD patients.

Belgian specialty chemical company (Euronext: SOLB, HQ Brussels; ~€4.9B revenue after 2023 split); major global HF (hydrogen fluoride) producer and the world's largest producer of fluorine-based specialty chemicals. Solvay's HF is produced at multiple European sites (Dombasle-sur-Meurthe, France; Rosignano, Italy) via reaction of fluorspar (CaF2) with sulfuric acid. HF is the gateway chemical for Solvay's entire fluorine chemistry chain: HF → fluoropolymers (PTFE, PVDF), refrigerants (HFCs/HFOs), specialty fluorinated gases (NF3 precursor), and electronic-grade HF for semiconductors. Solvay split into two companies in December 2023 — the new 'Solvay' retained the specialty chemicals (including HF and fluorine) while 'Syensqo' retained the advanced materials — so the HF supply chain is now within the post-split Solvay entity. Solvay was founded in 1863 by Ernest Solvay, inventor of the Solvay process for soda ash (sodium carbonate) production — the same Belgian industrial dynasty that revolutionized 19th-century chemical manufacturing now controls a critical node in 21st-century semiconductor supply chains.

Indian generic pharmaceutical company and the world's largest generic inhaler manufacturer by volume. Pioneer of generic salbutamol inhalers in India (1978). Manufactures generic pMDIs at scale. Received FDA final approval for generic Proventil HFA. Critical supplier during COVID-19 when global inhaler demand surged.

American industrial conglomerate (Nasdaq: HON, HQ Charlotte NC; ~$36B revenue); Advanced Materials division produces HF and a range of fluorinated specialty chemicals at Geismar Louisiana (one of the world's largest HF and fluoropolymer production sites). Honeywell's Geismar LA facility is a major supplier of HF to industrial and specialty chemical markets, as well as fluorinated refrigerants (Solstice series HFOs) and NF3 precursor HF. Honeywell's fluorine chemistry heritage traces to AlliedSignal (merged with Honeywell 1999) which itself acquired the fluorine chemistry business of Allied Chemical — which owned the original US fluorspar-to-HF process patents dating to the Manhattan Project era, when HF was needed for uranium enrichment (UF6 gaseous diffusion). The same US HF production infrastructure built for nuclear weapons development now supplies semiconductor-grade fluorinated gases.

American industrial conglomerate (Nasdaq: HON, HQ Charlotte NC; ~$36B revenue); Performance Materials and Technologies division produces HFA-134a refrigerant and pharmaceutical-grade propellant, as well as next-generation low-GWP alternatives including Solstice® HFO-1234yf (automotive AC replacement) and HFA-152a (low-GWP pMDI propellant for next-generation inhalers). Honeywell is developing pharmaceutical-grade HFA-152a as the primary replacement for HFA-134a in pMDIs as EU F-gas regulations phase down 134a — GWP of 152a is 4 vs 1,430 for 134a, meeting European climate targets. AstraZeneca, GlaxoSmithKline, and other pharma companies are partnering with Honeywell to develop and qualify HFA-152a-propelled inhalers for regulatory submission. Honeywell's position as both an HFA-134a producer AND a leading HFA-152a developer gives it a unique role in the regulatory transition threatening the current pMDI supply chain.

Italian specialty valve and actuator manufacturer (HQ Carnago, Varese, Lombardy; private, family-owned; ~€350M revenue); the third-tier supplier in pMDI metering valves behind Bespak and Aptar Pharma. Coster Group manufactures pMDI metering valves for generic inhaler manufacturers and some branded products, predominantly serving European and Latin American markets. Coster also manufactures aerosol valves for personal care products (hairspray, deodorant) and industrial applications — the same Italian valve engineering company that makes the valve in a can of Axe body spray also makes the metering valve that delivers albuterol in some generic asthma inhalers. Coster's position in the pMDI valve market represents a strategic supply diversification option for pharmaceutical companies seeking alternatives to the Bespak/Aptar duopoly, though its smaller scale and qualification breadth limits uptake.

Indian pharmaceutical company (NSE: SUNPHARMA, HQ Mumbai; ~₹600B revenue); world's fourth-largest specialty generic pharmaceutical company and India's largest pharma company by market cap. Sun Pharma manufactures salbutamol sulfate API and finished albuterol inhalers (pMDI and nebulizer solution) at multiple Indian manufacturing sites, supplying US and global generic markets through its Taro Pharmaceutical US subsidiary. Sun Pharma was founded in 1983 by Dilip Shanghvi, who started with just five pharmaceutical products and a single employee; today Sun Pharma employs 36,000 people and operates 43 manufacturing sites globally. Sun Pharma's founder Dilip Shanghvi is now one of India's wealthiest individuals — his journey from a $1M startup to a $30B market cap company in 40 years is one of the defining business stories of India's pharmaceutical sector rise.

Teva Pharmaceutical Industries Ltd. (Tel Aviv Israel; NYSE: TEVA; ~$15.9B revenue 2023; world's largest generic pharmaceutical company by revenue) is a significant manufacturer and distributor of generic carboplatin injectable in the US market. Teva's API division (TAPI) and finished-dose operations supply generic oncology products including carboplatin to US hospital pharmacies. Teva experienced its own FDA enforcement actions in this period — in 2022, Teva's Irvine California facility was shut down due to contamination and sterilization failures, causing a separate streptozocin (pancreatic cancer drug) shortage. Teva's manufacturing is concentrated in Israel, India, and Eastern Europe, with US finished-dose manufacturing in North America. Teva's scale as the world's largest generic company makes it a critical backstop supplier when primary market participants face disruptions.

Italian specialty pharmaceutical aerosol component manufacturer (HQ Senago, Milan; private); produces pharmaceutical-grade aluminum canisters for pMDI inhalers as one of the few alternatives to H&T Presspart. EMSAR serves primarily European generic inhaler manufacturers seeking second-source canister supply for risk mitigation. EMSAR's canister production is significantly smaller than H&T Presspart but provides a qualified alternative source for pharmaceutical companies willing to invest in dual-sourcing qualification programs. Italian precision manufacturing tradition in metalworking supports pharmaceutical-grade aluminum drawing operations.